文献速递糖尿病

冠状动脉疾病患者的血糖异常筛查及其预后影响:来自EUROASPIRE IV和V队列研究的经验

Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-09-23

该队列研究纳入24个欧洲国家79个中心(EAIV)和27个欧洲国家131个中心(EAV)的冠心病无糖尿病患者,比较空腹血糖、HbA1c和口服葡萄糖耐量试验的诊断与预测效能。结果显示2hPG在检测血糖异常和预测心血管事件方面优于HbA1c,作者建议将2hPG作为主要筛查工具。

要点

  • 在冠心病患者中,OGTT诊断的2型糖尿病检出率高于HbA1c(22.5% vs 4.2%)。
  • 2hPG≥9 mmol/L和HbA1c≥5.9%是心血管事件的最强预测因子,而FPG无预测作用。
  • 作者认为2hPG在检测血糖异常和预测心血管事件方面优于HbA1c,应推荐作为主要筛查工具。

核心结论

  • 2hPG在检测血糖异常和预测未来心血管事件方面似乎优于HbA1c,应推荐作为主要筛查工具。

研究设计与样本

  • 该研究为队列研究,基于EUROASPIRE IV(2012-13)和V(2016-17)研究,在24个欧洲国家79个中心(EAIV)和27个欧洲国家131个中心(EAV)开展。
  • 纳入年龄18-80岁、无糖尿病、在调查前6-36个月(EAIV)或6-24个月(EAV)诊断为冠状动脉疾病的患者。
  • 患者接受OGTT(FPG和2小时负荷后血糖[2-hPG])和HbA1c检测,分析限于同时有OGTT和HbA1c数据的患者。
  • 随访通过问卷在基线调查至少1年后进行,结局分析限于有有效随访数据的患者。
  • 分析人群共8364例(EAIV 3932例,EAV 4432例),其中7892例有心血管事件信息,中位随访1.6年(IQR 1.2-2.0)。

主要发现

  • 基线时,8263例患者中1856例(22.5%)经OGTT单独诊断为新发2型糖尿病,而346例(4.2%)经HbA1c单独诊断。
  • 根据2hPG,3896例(47.1%)患者存在新发血糖异常(新发2型糖尿病或IGT)。
  • 2hPG≥9 mmol/L(162 mg/dL)预测心血管事件的aHR为1.58(95%CI 1.27-1.95,p<0.0001),HbA1c≥5.9%(41 mmol/mol)的aHR为1.48(95%CI 1.19-1.84,p=0.0010),而FPG无预测作用。
  • 多变量模型显示,HbA1c对心血管事件的影响主要由2hPG解释(HbA1c每增加1单位的aHR为1.13,95%CI 0.98-1.30,p=0.11;Ln[2hPG]每增加1单位的aHR为1.37,95%CI 1.08-1.74,p=0.0042)。
  • 平均患者年龄63.3岁(SD 9.8),8364例中6346例(75.9%)为男性。

关键数值与推荐

  • 新发2型糖尿病诊断:OGTT单独诊断1856/8263例(22.5%),HbA1c单独诊断346/8263例(4.2%)。
  • 新发血糖异常(新发2型糖尿病或IGT)根据2hPG诊断3896例(47.1%)。
  • 2hPG≥9 mmol/L(162 mg/dL)预测心血管事件aHR 1.58(95%CI 1.27-1.95,p<0.0001)。
  • HbA1c≥5.9%(41 mmol/mol)预测心血管事件aHR 1.48(95%CI 1.19-1.84,p=0.0010)。
  • FPG未预测心血管事件。

临床怎么用

  • 作者认为2hPG在检测血糖异常和预测心血管事件方面优于HbA1c,应推荐作为主要筛查工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucose perturbations can be detected by fasting plasma glucose (FPG), HbA1c, and the oral glucose tolerance test (OGTT). The highest yield is provided by OGTT. HbA1c is considered more practical. We compare the diagnostic and predictive performance of these glycaemic indicators based on combined data from the EUROASPIRE IV (EAIV) and V (EAV) studies. METHODS: This cohort study was conducted in 79 centres in 24 European countries (EAIV) and 131 centres in 27 European countries (EAV). Eligible patients were aged 18-80 years, did not have diabetes, and were diagnosed with coronary artery disease 6-36 months (EAIV) or 6-24 months (EAV) before the investigation. Patients were investigated with OGTT (FPG and 2 h post-load glucose [2-hPG]) and HbA1c. Follow-up of subsequent cardiovascular events was done by means of a questionnaire at least 1 year after the baseline investigation. Analyses were done in patients with both OGTT and HbA1c data available. Outcome analysis in these patients was restricted to those with valid follow-up data available. FINDINGS: 16 259 patients were interviewed in EAIV (2012-13) and EAV (2016-17). 8364 patients had both OGTT and HbA1C data and were included in the analysis population (3932 in EAIV and 4432 in EAV). Information on cardiovascular events was available in 7892 patients. Follow-up was for a median 1·6 years (IQR 1·2-2·0). The average patient age was 63·3 years (SD 9·8), and 6346 (75·9%) of 8364 patients were men. At baseline, 1856 (22·5%) of 8263 patients were determined to have newly detected type 2 diabetes using OGTT alone, compared with 346 (4·2%) using HbA1c alone. New dysglycaemia, defined as newly detected type 2 diabetes or impaired glucose tolerance (IGT), was present in 3896 (47·1%) of the patients according to 2hPG. 2hPG 9 mmol/L or greater (162 mg/dL, adjusted hazard ratio [aHR] 1·58; 95% CI 1·27-1·95, p<0·0001), and HbA1c 5·9% or greater (41 mmol/mol, aHR 1·48, 1·19-1·84; p=0·0010) were the strongest predictors of cardiovascular events, while FPG did not predict. A multivariable model showed that the effect of HbA1c on cardiovascular events was mainly explained by 2hPG (aHR for 1 unit increase in HbA1c 1·13, 0·98-1·30; p=0·11; and aHR for 1 unit increase in Ln[2hPG] 1·37, 1·08-1·74; p=0·0042). INTERPRETATION: 2hPG appears better than HbA1c in detecting dysglycaemia and predicting its impact on future cardiovascular events in patients with coronary artery disease and should be recommended as the primary screening tool. FUNDING: Swedish Heart-Lung Foundation, Region Stockholm (ALF), the Erling Persson Foundation, the Baltic Child Foundation.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Ferrannini G, Tuomilehto J, De Backer G, et al. Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies. Lancet Diabetes Endocrinol. 2024. PMID: 39326426. doi:10.1016/S2213-8587(24)00201-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。